Skip to content

Impact of the new 2024 ESC blood pressure classification in a low-risk cohort: the 70 mmhg diastolic threshold may reduce risk discrimination in primary prevention.

Sep 2026 · Journal of Hypertension · 0 citations · 19 references
Medicine

TL;DR

Lowering the diastolic threshold to 70 mmHg produced substantial reclassification but did not identify an independent higher-risk phenotype when systolic BP remained < 120 mmHg, questioning the relevance of such a low diastolic threshold for elevated BP in the new ESC 2024 classification.

Abstract

In 2024, the European Society of Cardiology (ESC) hypertension guidelines introduced an "elevated blood pressure" category (120-139 and/or 70-89 mmHg), lowering the diastolic threshold from 85 to 70 mmHg. Its relevance for cardiovascular risk stratification in low-risk primary prevention remains uncertain. We conducted a cross-sectional study of 1394 adults undergoing standardized preventive health assessment in France, with office blood pressure (BP) measured using a validated oscillometric device. Participants were classified by ESC/ESH 2018 and ESC 2024 definitions. We quantified category shifts and compared the clinical, lifestyle and biological profile of individuals reclassified from 2018 optimal to 2024 elevated on the basis of diastolic BP ≥70 mmHg (systolic BP < 120 mmHg) vs. those remaining nonelevated. SCORE2, available in 61% of participants, was used as a supporting risk estimate. ESC 2024 classified 10.0% as nonelevated, 64.2% as elevated and 25.8% as hypertensive; 70% of previously "optimal" individuals became "elevated." Compared with nonelevated peers, the diastolic-only reclassified group differed only in age (45.5 vs. 42.7 years; P = 0.007), with no difference in sex, body mass index, lifestyle, cardiovascular history or biomarkers. Their slightly higher SCORE2 was attributable to higher systolic BP and age, and was no longer significant after adjustment for systolic BP. By contrast, individuals reclassified from normal to elevated had a less favorable cardiometabolic profile. Lowering the diastolic threshold to 70 mmHg produced substantial reclassification but did not identify an independent higher-risk phenotype when systolic BP remained < 120 mmHg, questioning the relevance of such a low diastolic threshold for elevated BP in the new ESC 2024 classification. Prospective outcome studies are needed.

View source

Similar papers

Open access Sep 2026

Reclassification of office blood pressure categories according to the 2024 European Society of Cardiology guidelines and its implications for clinical practice in primary care: a cross-sectional study

The 2024 European Society of Cardiology (ESC) guidelines retained the diagnostic threshold for hypertension (≥ 140/90 mmHg) but revised the classification of office blood pressure (BP) values below this threshold and introduced a risk-based management strategy. However, there are limited data regarding the impact of th...

Ismail Cifci, E. Koç · 0 citations
Open access Aug 2026

Body mass index modifies cardiovascular risk across blood pressure categories, particularly among underweight adults with hypertension: a 6.3 million‑person nationwide Japanese cohort study.

It is suggested that higher blood pressure may amplify the adverse prognostic significance of underweight, as well as the association between body mass index category and 10-year risk of major adverse cardiovascular events differed across blood pressure categories.

T. Kawano, Tomohisa Seki, Hiroaki Araie et al. · 1 citation
Open access Sep 2026

Hypertension prevalence, detection, treatment and control among 1.4 million adults in England: a cross-sectional analysis from the Our Future Health study in 2022–2025

Over one-third of adults in England had hypertension, yet only half of affected individuals were detected and half of those treated achieved blood pressure control, highlighting the need for population-wide prevention strategies alongside targeted treatment of individuals at high cardiovascular risk.

Wen-Yu Liu, J. Collister, T. Littlejohns et al. · 0 citations
Open access Sep 2026

Distribution of Cardiovascular Disease Risk Based on the Updated 2023 Guideline‐Recommended Australian Cardiovascular Disease Risk Algorithm and Comparison With the 2012 Algorithm: An Observational Study

ABSTRACT Objectives To quantify cardiovascular disease (CVD) risk, and implications for targeting preventive pharmacotherapy, using the 2023 guideline‐recommended Australian CVD risk algorithm, and compare this to the previous (2012) algorithm. Study Type Application and comparison of two risk prediction algorithms. Se...

N. Lazarevic, M. Bhat, Grace Joshy et al. · 0 citations
Review Open access Oct 2026

Guideline-Directed Treatment Eligibility and Burden of Untreated Stage-1 Hypertension Under the 2025 American College of Cardiology/American Heart Association Hypertension Guideline: Insights From NHANES 2015 to 2020.

The 2025 American College of Cardiology/American Heart Association hypertension guideline recommendations were largely concordant with the prior guideline among adults with untreated stage 1 hypertension, while still newly identifying a subset of individuals with elevated cardiometabolic risk who may benefit from earli...

Qi Jian, Yi-Shan Chen, M. Ruzieh et al. · 0 citations
Open access Sep 2026

SCORE2-OP-guided statin initiation for primary prevention in adults aged 70-89 years without diabetes: evidence for age-specific risk thresholds.

Age-specific risk thresholds of the SCORE2-OP estimated risk may be further developed and considered when weighing the benefits of initiating primary prevention of incident CVD with statins in non-diabetic adults aged 70+.

Lluís Zacarías-Pons, J. Blanch, L. Alves-Cabratosa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.